Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer

Inclusion Criteria: * age \> 18 years * gemcitabine-refractory, histologically confirmed pancreatic cancer (progression during or within 6 months of first-line treatment) * locally advanced or metastatic disease with measurable or non-measurable disease * life expectancy of greater than 10 weeks * prior treatment with investigational therapies including EGFR and VEGF antagonists is allowed when administered\>4 weeks prior to start of therapy Exclusion Criteria: * any serious uncontrolled medical condition * prior radiation treatment is not allowed * no prior chemotherapy within the previous 4 weeks * known peripheral neuropathy \> CTCAE v 3.0 grade 1; absence of the deep tendon reflexes as the sole neurological abnormality does not render the patient ineligible * known brain metastases * lack of physical integrity of the upper GI tract, malabsorption syndrome, or inability to take oral medication * fertile women (\<2 years after last menstruation) and men of childbearing potential not willing to use effective contraception * pregnancy or breast feeding